PCI Biotech is a biopharmaceutical company that produces therapies to fight against cancer through creating photochemical internalisation (PCI) technology platform. This platform is divided into 3 different segments such as: fimaCHEM, fimaVACC and fimaNAc. FimaCHEM is the company's main programme and it focuses on studying bile duct cancer. The fimaVACC studies the cytotoxic effect of therapeutic cancer vaccines. The fimaNAc is used to provide the delivery of nucleic acids: mRNA and siRNA. PCI Biotech was founded in 2000 and is based in Lysaker, Norway. They are a subsidiary of PCI Biotech Holding ASA.